These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11810598)

  • 1. Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients.
    Chêne G; Angelini E; Cotte L; Lang JM; Morlat P; Rancinan C; May T; Journot V; Raffi F; Jarrousse B; Grappin M; Lepeu G; Molina JM
    Clin Infect Dis; 2002 Mar; 34(5):649-57. PubMed ID: 11810598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy.
    Galli M; Ridolfo AL; Adorni F; Cappelletti A; Morelli P; Massetto B; Piazza M; Gianelli E; Vaccarezza M; Gervasoni C; Moroni M
    Antivir Ther; 2003 Aug; 8(4):347-54. PubMed ID: 14518704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the risk factors associated with lipodystrophy development in a cohort of HIV-positive patients.
    Seminari E; Tinelli C; Minoli L; Sacchi P; Filice G; Zocchetti C; Meneghetti G; Bruno R; Maserati R
    Antivir Ther; 2002 Sep; 7(3):175-80. PubMed ID: 12487384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy.
    Savès M; Raffi F; Capeau J; Rozenbaum W; Ragnaud JM; Perronne C; Basdevant A; Leport C; Chêne G;
    Clin Infect Dis; 2002 May; 34(10):1396-405. PubMed ID: 11981737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidémiologie Clinique du Syndrome d'Immunodéficience Acquise en Aquitaine.
    Thiébaut R; Daucourt V; Mercié P; Ekouévi DK; Malvy D; Morlat P; Dupon M; Neau D; Farbos S; Marimoutou C; Dabis F
    Clin Infect Dis; 2000 Dec; 31(6):1482-7. PubMed ID: 11096016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda.
    van Griensven J; De Naeyer L; Mushi T; Ubarijoro S; Gashumba D; Gazille C; Zachariah R
    Trans R Soc Trop Med Hyg; 2007 Aug; 101(8):793-8. PubMed ID: 17467756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy.
    Estrada V; Martínez-Larrad MT; González-Sánchez JL; de Villar NG; Zabena C; Fernández C; Serrano-Ríos M
    Metabolism; 2006 Jul; 55(7):940-5. PubMed ID: 16784968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial.
    Molina JM; Marcelin AG; Pavie J; Heripret L; De Boever CM; Troccaz M; Leleu G; Calvez V;
    J Infect Dis; 2005 Mar; 191(6):840-7. PubMed ID: 15717257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients.
    Milinkovic A; Martinez E; López S; de Lazzari E; Miró O; Vidal S; Blanco JL; Garrabou G; Laguno M; Arnaiz JA; Leon A; Larrousse M; Lonca M; Mallolas J; Gatell JM
    Antivir Ther; 2007; 12(3):407-15. PubMed ID: 17591031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry.
    Tavassoli N; Bagheri H; Sommet A; Delpierre C; Marion-Latard F; Massip P; Aquilina C; Bonnet E; Obadia M; Labau E; Montastruc JL; Bernard J
    Pharmacotherapy; 2006 Feb; 26(2):154-61. PubMed ID: 16466321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipodystrophy and dyslipidemia in human immunodeficiency virus-infected Thai patients receiving antiretroviral therapy.
    Chuapai Y; Kiertiburanakul S; Malathum K; Sungkanuparph S
    J Med Assoc Thai; 2007 Mar; 90(3):452-8. PubMed ID: 17427520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy.
    Buffet M; Schwarzinger M; Amellal B; Gourlain K; Bui P; Prévot M; Deleuze J; Morini JP; Gorin I; Calvez V; Dupin N
    J Clin Virol; 2005 May; 33(1):60-4. PubMed ID: 15797366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load.
    Gil P; de Górgolas M; Estrada V; Arranz A; Rivas P; Yera C; García R; Granizo JJ; Fernández-Guerrero M
    Clin Infect Dis; 2004 Oct; 39(7):1024-9. PubMed ID: 15472856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study.
    Reliquet V; Allavena C; François-Brunet C; Perré P; Bellein V; Garré M; May T; Souala F; Besnier JM; Raffi F
    HIV Med; 2006 Oct; 7(7):431-6. PubMed ID: 16925728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute pancreatitis associated with different combination therapies in patients infected with human immunodeficiency virus.
    Guo JJ; Jang R; Louder A; Cluxton RJ
    Pharmacotherapy; 2005 Aug; 25(8):1044-54. PubMed ID: 16207094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.
    Negredo E; Paredes R; Bonjoch A; Tuldrà A; Fumaz CR; Gel S; Garcés B; Johnston S; Arnó A; Balagué M; Jou A; Tural C; Sirera G; Romeu J; Cruz L; Francia E; Domingo P; Arrizabalaga J; Ruiz I; Arribas JR; Ruiz L; Clotet B
    Antivir Ther; 1999; 4 Suppl 3():23-8. PubMed ID: 16021868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Host factors may be more important than choice of antiretrovirals in the development of lipoatrophy.
    McComsey G; Maa JF
    AIDS Read; 2003 Nov; 13(11):539-42, 559. PubMed ID: 14649623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
    Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The metabolic syndrome, an epidemic among HIV-infected patients on HAART.
    Jevtović DJ; Dragović G; Salemović D; Ranin J; Djurković-Djaković O
    Biomed Pharmacother; 2009 Jun; 63(5):337-42. PubMed ID: 18996676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
    Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
    HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.